Accent Therapeutics Targeting RNA-modifying proteins for novel precision cancer therapies Visit Site Careers
Aerovate Therapeutics Advancing novel therapies for people with rare cardiopulmonary disease NASDAQ: AVTE (2021) Visit Site Careers
Aiolos Bio Reimagining treatments for patients with respiratory illnesses and inflammatory conditions Sold to GSK (2024)
Akero Therapeutics Restoring metabolic balance to treat NASH and serious metabolic diseases NASDAQ: AKRO (2019) Visit Site Careers
Arkuda Therapeutics Targeting progranulin and lysosomal biology to treat neurodegenerative diseases Visit Site Careers
Bicycle Therapeutics Novel bicyclic peptides (bicycles) and bicycle drug conjugates for cancer NASDAQ: BCYC (2019) Visit Site Careers
Cadent Therapeutics Breakthrough therapies for neurological & psychiatric conditions Sold to Novartis (2020)
Comanche Biopharma Our mission is to develop the first treatment targeting a root cause of preeclampsia Visit Site
Day One Biopharmaceuticals Rapidly developing new cancer treatments for people of all ages NASDAQ: DAWN (2021) Visit Site Careers
deCODE genetics Population genetics for the discovery of novel drug targets Sold to Amgen (2012) Visit Site Careers
Diagonal Therapeutics Advancing a Ground-Breaking Approach to Agonist Antibody Therapeutics Visit Site Careers
Disarm Therapeutics Preventing axonal degeneration in patients with neurological diseases Sold to Lilly (2020)
Dyne Therapeutics Pioneering targeted therapies for serious muscle diseases NASDAQ: DYN (2020) Visit Site Careers
F-Star Alpha Limited Novel bispecific antibodies platform Sold to invoX Pharma (2023) Visit Site Careers
Generation Bio Scalable, re-dosable, non-viral gene therapy for genetic diseases NASDAQ: GBIO (2020) Visit Site Careers
GRObio Genomically recoded organism platform for the development of protein therapeutics Visit Site Careers
Harbour Antibodies Mouse platforms for the generation of fully human antibodies Sold to Harbour BioMed (2016)
HotSpot Therapeutics Unlocking nature's regulatory mechanisms to fuel the discovery of new medicines Visit Site Careers
IFM Therapeutics Targeting the innate immune system to treat cancer and inflammatory diseases Sold to BMS (2017); Novartis (2019) Visit Site Careers
K36 Therapeutics Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics Visit Site
Kailera Therapeutics Advancing next-generation therapies for obesity and related conditions Visit Site Careers
Kymera Therapeutics Delivering novel small molecule protein degrader medicines Nasdaq: KYMR (2020) Visit Site Careers
Lifordi Immunotherapeutics Among the first to leverage ADC success to develop treatments for autoimmune and inflammatory disorders Visit Site
Lysosomal Therapeutics, Inc. Novel therapies for severe neurodegenerative diseases Sold to Bial in 2020
Mariana Oncology Treating cancer's toughest tumors through innovation in precision radiopharmaceuticals Sold to Novartis (2024) Visit Site Careers
Matchpoint Therapeutics Discovering precision covalent medicines for immune diseases Visit Site Careers
nChroma Bio Best-in-class epigenetic editing & targeted in vivo delivery technology to reach the full potential of genetic medicines Visit Site
Nimbus Therapeutics Breakthrough computer-aided drug design for transformative medicines Visit Site Careers
Q32 Bio Targeting regulators of innate and adaptive immunity to restore immune homeostasisNASDAQ: QTTB (2024) Visit Site Careers
Rectify Restoring ABC transporter function for patients with serious genetic diseases Visit Site Careers
Replimune Next-generation oncolytic immuno-therapies for cancer treatment NASDAQ: REPL (2018) Visit Site Careers
Rodin Therapeutics Enhancing synaptic integrity for treatment of neurological disorders Sold to Alkermes (2019)
Sionna Therapeutics Developing highly effective, differentiated treatments for cystic fibrosisNASDAQ: SION (2025) Visit Site Careers
Spero Therapeutics Novel antibiotics for drug-resistant bacterial infections NASDAQ: SPRO (2017) Visit Site Careers
Surface Oncology Novel antibodies built to break through the tumor microenvironment Sold to Coherus (2023)
Synlogic Pioneering transformative new biotherapeutics for patients NASDAQ: SYBX (2017) Visit Site Careers
Third Harmonic Bio Advancing medicines for allergy and inflammation NASDAQ: THRD (2022) Visit Site Careers
Trace Neuroscience Antisense oligonucleotide therapeutics for genetically driven diseases with high unmet medical need including ALS Visit Site Careers
Vedere Bio Next-generation ocular gene therapies for vision restoration and preservation Sold to Novartis (2020)
Versanis Bio Transformative treatments for people with obesity and other cardiometabolic diseases Sold to Lilly (2023)
Vigil Neuroscience Harnessing the power of microglia to transform treatments for neuro-degenerative diseases NASDAQ: VIGL (2022) Visit Site Careers
Vitae Pharmaceuticals Novel therapeutics using proprietary computational chemistry Sold to Allergan (2016)
Xilio Therapeutics Harnessing the immune system to defeat cancer with tumor-selective immunotherapies NASDAQ: XLO (2021) Visit Site Careers